Hematologic risk factors of vascular disease and their relation to dementia

Dementia and Geriatric Cognitive Disorders

Volumn 21, Issue 5-6, 2006, Pages 335-352

  Mielke, Michelle M ^a   Zandi, Peter P ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antioxidants; Blood brain barrier; C reactive protein; Cholesterol; Dementia, hematologic risk factors; Dementia, vascular disease; Fatty acids; Homocysteine; Vascular dementia

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN E; ASCORBIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL DERIVATIVE; FATTY ACID; HOMOCYSTEINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

BLOOD ANALYSIS; CORRELATION ANALYSIS; DEMENTIA; DIET; EVIDENCE BASED MEDICINE; HUMAN; LIFESPAN; LONGITUDINAL STUDY; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR DISEASE;

ASCORBIC ACID; BLOOD-BRAIN BARRIER; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; DEMENTIA, VASCULAR; FATTY ACIDS; HOMOCYSTEINE; HUMANS; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VITAMIN E;

EID: 33646706106     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091789     Document Type: Review

References (195)

1. Jorm AF, Jolley D: The incidence of dementia: a meta-analysis. Neurology 1998;51:728-733.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122.
3. Ernst RL, Hay JW: The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-1264.
4. Vinters HV: Cerebral amyloid angiopathy. A critical review. Stroke 1987;18:311-324.
5. Kalaria RN, Hedera P: Differential degeneration of the cerebral microvasculature in Alzheimer's disease. Neuroreport 1995;6:477-480.
6. Perlmutter LS, Chui HC: Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 1990;24:677-686.
7. Sparks DL, Hunsaker JC 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR: Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990;11:601-607.
8. Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC 3rd: Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol 1993;52:135-142.
9. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
10. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ: Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2000;21:49-55.
11. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-154.
12. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A: Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-321.
13. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K, et al: Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;45:1161-1168.
14. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999;53:1937-1942.
15. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I: An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524-1528.
16. Hoyer S: The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 2002;109:341-360.
17. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R: Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60:1707-1712.
18. Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003;17:27-45.
19. Mudd SH, Cantoni GL: Biological transmethylation methyl-group neogenesis and other one carbon metabolic reactions dependent upon tetrahydrofolic acid; in Florkin M, Stot E (eds): Comprehensive Biochemistry. Amsterdam, Elsevier, 1964, vol 15, pp 1-147.
20. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH: Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764-1779.
21. Kang SS, Wong PW, Norusis M: Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-462.
22. Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B: Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87.
23. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-1533.
24. 12 (cblE and cblG). Clin Invest Med 1989;12:270-271.
25. Nilsson K, Gustafson L, Hultberg B: The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. Clin Chem 2000;46:691-696.
26. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373.
27. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D: Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001;81:645-672.
28. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA: Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-1121.
29. Harker LA, Slichter SJ, Scott CR, Ross R: Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-543.
30. Blundell G, Jones BG, Rose FA, Tudball N: Homocysteine-mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996;122:163-172.
31. Blom HJ, Engelen DP, Boers GH, Stadhouders AM, Sengers RC, de Abreu R, TePoele-Pothoff MT, Trijbels JM: Lipid peroxidation in homocysteinaemia. J Inherit Metab Dis 1992;15:419-422.
32. Frauscher G, Karnaukhova E, Muehl A, Hoeger H, Lubec B: Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid-additional mechanisms in homocysteine induced endothelial damage? Life Sci 1995;57:813-817.
33. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923-5928.
34. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP: Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6926.
35. Parnetti L, Bottiglieri T, Lowenthal D: Role of homocysteine in age-related vascular and non-vascular diseases. Aging (Milano) 1997;9:241-257.
36. McCaddon A, Kelly CL: Alzheimer's disease: a 'cobalaminergic' hypothesis. Med Hypotheses 1992;37:161-165.
37. 12 and folate. Br Med Bull 1999;55:669-682.
38. Nilsson K, Gustafson L, Faldt R, Andersson A, Brattstrom L, Lindgren A, Israelsson B, Hultberg B: Hyperhomocysteinaemia - a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-859.
39. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G: Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism 2001;50:1466-1471.
40. 12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci 1997;52:M76-M79.
41. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-239.
42. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD: Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002;59:787-793.
43. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, Regland B: Alzheimer's disease and total plasma aminothiols. Biol Psychiatry 2003;53:254-260.
44. Selley ML: Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 2003;24:903-907.
45. Anello G, Gueant-Rodriguez RM, Bosco P, Gueant JL, Romano A, Namour B, Spada R, Caraci F, Pourie G, Daval JL, Ferri R: Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease. Neuroreport 2004;15:859-861.
46. 12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med 2004;42:1032-1035.
47. 6 and folate intake in AD and healthy aging. J Nutr Health Aging 2003;7:160-165.
48. Nilsson K, Gustafson L, Hultberg B: Plasma homocysteine concentration relates to the severity but not to the duration of Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:666-672.
49. 12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004;80:114-122.
50. Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M: Homocysteine in cerebral macroangiography and microangiopathy. Lancet 1999;353:1586-1587.
51. Leblhuber F, Walli J, Artner-Dworzak E, Vrecko K, Widner B, Reibnegger G, Fuchs D: Hyperhomocysteinemia in dementia. J Neural Transm 2000;107:1469-1474.
52. Nilsson K, Gustafson L, Hultberg B: Relation between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:7-12.
53. 6, and vascular disease in AD patients. Neurology 2002;58:1471-1475.
54. 12, folate, homocysteine and dementia: are they really related? Arch Gerontol Geriatr 2005;40:139-146.
55. 12 or homocysteine, is associated with dementia in elderly Latinos. J Nutr Health Aging 2005;9:39-43.
56. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
57. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
58. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R: Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004;62:1972-1976.
59. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
60. Ettinger WH, Wahl PW, Kuller LH, Bush TL, Tracy RP, Manolio TA, Borhani NO, Wong ND, O'Leary DH: Lipoprotein lipids in older people. Results from the Cardiovascular Health Study. The CHS Collaborative Research Group. Circulation 1992;86:858-869.
61. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, Patsch W: Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;13:1139-1158.
62. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C: Coronary heart disease risk factors and menopause: a study in 1,684 French women. Atherosclerosis 1999;142:415-423.
63. Labarthe DR: Adverse blood lipid profile; in Colilla J (ed): Epidemiology and Prevention of Cardiovascular Diseases. A Global Challenge. Gaithersburg, Aspen Publishers Inc, 1998, pp 223-260.
64. Ginsberg HN: Lipoprotein metabolism and its relationship to atherosclerosis. Med Clin North Am 1994;78:1-20.
65. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR: Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994;126:88-94.
66. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-6464.
67. Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T: Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-5861.
68. Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alperovitch A: APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005;64:1531-1538.
69. Lesser G, Kandiah K, Libow LS, Likourezos A, Breuer B, Marin D, Mohs R, Haroutunian V, Neufeld R: Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:138-145.
70. Lehtonen A, Luutonen S: High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia. Age Ageing 1986;15:267-270.
71. Erkinjuntti T, Sulkava R, Tilvis R: Is determination of plasma lipids useful in the differentiation of multi-infarct dementia from Alzheimer's disease? Compr Gerontol [A] 1988;2:1-6.
72. Bonarek M, Barberger-Gateau P, Letenneur L, Deschamps V, Iron A, Dubroca B, Dartigues JF: Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000;19:141-148.
73. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Kervinen K, Kesaniemi YA, Riekkinen PJ, Laakso M: Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross-sectional population based study. BMJ 1997;315:1045-1049.
74. Scacchi R, De Bernardini L, Mantuano E, Vilardo T, Donini LM, Ruggeri M, Gemma AT, Pascone R, Corbo RM: DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:186-190.
75. Siest G, Bertrand P, Qin B, Herbeth B, Serot JM, Masana L, Ribalta J, Passmore AP, Evans A, Ferrari M, Franceschi M, Shepherd J, Cuchel M, Beisiegel U, Zuchowsky K, Rukavina AS, Sertic J, Stojanov M, Kostic V, Mitrevski A, Petrova V, Sass C, Merched A, Salonen JT, Tiret L, Visvikis S: Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med 2000;38:721-730.
76. Czyzewski K, Lalowski MM, Pfeffer A, Barcikowska M: Lipid metabolism parameters in patients with Alzheimer's disease and their first degree relatives. Acta Neurobiol Exp (Wars) 2001;61:21-26.
77. Kim JM, Stewart R, Shin IS, Yoon JS: Low cholesterol, cognitive function and Alzheimer's disease in a community population with cognitive impairment. J Nutr Health Aging 2002;6:320-323.
78. Suryadevara V, Storey SG, Aronow WS, Ahn C: Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci 2003;58:M859-M861.
79. Caramelli P, Nitrini R, Maranhao R, Lourenco AC, Damasceno MC, Vinagre C, Caramelli B: Increased apolipoprotein B serum concentration in Alzheimer's disease. Acta Neurol Scand 1999;100:61-63.
80. Watanabe T, Koba S, Kawamura M, Itokawa M, Idei T, Nakagawa Y, Iguchi T, Katagiri T: Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. Metabolism 2004;53:476-482.
81. Muckle TJ, Roy JR: High-density lipoprotein cholesterol in differential diagnosis of senile dementia. Lancet 1985;i:1191-1193.
82. Giubilei F, D'Antona R, Antonini R, Lenzi GL, Ricci G, Fieschi C: Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol Scand 1990;81:84-86.
83. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A: Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
84. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-1451.
85. Mainous AG 3rd, Eschenbach SL, Wells BJ, Everett CJ, Gill JM: Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: results from an 18-year population-based cohort. Fam Med 2005;37:36-42.
86. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K: Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-281.
87. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, D'Agostino RB, Wolf PA: Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003;163:1053-1057.
88. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, Ross GW, Havlik RJ, Launer LJ: Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol 2000;20:2255-2260.
89. Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, Stern Y, Mayeux R: Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254-260.
90. Romas SN, Tang MX, Berglund L, Mayeux R: APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999;53:517-521.
91. Reitz C, Tang MX, Luchsinger J, Mayeux R: Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705-714.
92. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, Skoog I: High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64:1689-1695.
93. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.
94. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
95. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, Hui DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ, et al: A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989;83:1015-1031.
96. Beffert U, Poirier J: Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann NY Acad Sci 1996;777:166-174.
97. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, Hendrie H: Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African-Americans. Neurology 2000;54:240-242.
98. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H: Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-155.
99. Jurevics H, Morell P: Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 1995;64:895-901.
100. Bjorkhem I, Meaney S: Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004;24:806-815.
101. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH: Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987;262:14352-14360.
102. Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, Bjorkhem I: Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 1996;93:9799-9804.
103. Bjorkhem I, Lütjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J: Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 1998;39:1594-1600.
104. Lütjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K, Heun R: Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000;41:195-198.
105. Bretillon L, Siden A, Wahlund LO, Lütjohann D, Minthon L, Crisby M, Hillert J, Groth CG, Diczfalusy U, Bjorkhem I: Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 2000;293:87-90.
106. Kolsch H, Heun R, Kerksiek A, Bergmann KV, Maier W, Lütjohann D: Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci Lett 2004;368:303-308.
107. Teunissen CE, De Vente J, von Bergmann K, Bosma H, van Boxtel MP, De Bruijn C, Jolles J, Steinbusch HW, Lütjohann D: Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol Aging 2003;24:147-155.
108. Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Bjorkhem I, von Bergmann K, Heun R: Plasma 24S- hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000;11:1959-1962.
109. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000;356:1627-1631.
110. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
111. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I: Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-227.
112. De Caterina R, Madonna R, Zucchi R, La Rovere MT: Antiarrhythmic effects of ω-3 fatty acids: from epidemiology to bedside. Am Heart J 2003;146:420-430.
113. Hu FB: The balance between ω-6 and ω-3 fatty acids and the risk of coronary heart disease. Nutrition 2001;17:741-742.
114. Yehuda S, Carasso RL: Modulation of learning, pain thresholds, and thermoregulation in the rat by preparations of free purified α-linolenic and linoleic acids: determination of the optimal ω3-to-ω6 ratio. Proc Natl Acad Sci USA 1993;90:10345-10349.
115. De Caterina R, Liao JK, Libby P: Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000;71:213S-223S.
116. Leeson CP, Whincup PH, Cook DG, Mullen MJ, Donald AE, Seymour CA, Deanfield JE: Cholesterol and arterial distensibility in the first decade of life: a population-based study. Circulation 2000;101:1533-1538.
117. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ: Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000;102:1264-1269.
118. Von Schacky C: Prophylaxis of atherosclerosis with marine ω3 fatty acids. A comprehensive strategy. Ann Intern Med 1987;107:890-899.
119. Harris WS: Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989;30:785-807.
120. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477-485.
121. Clarke SD: Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr 2001;131:1129-1132.
122. Simopoulos AP: Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999;70:560S-569S.
123. Rapoport SI: In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 2001;16:243-261.
124. Martin RE, Bazan NG: Changing fatty acid content of growth cone lipids prior to synaptogenesis. J Neurochem 1992;59:318-325.
125. Choe M, Jackson C, Yu BP: Lipid peroxidation contributes to age-related membrane rigidity. Free Radic Biol Med 1995;18:977-984.
126. Urano S, Sato Y, Otonari T, Makabe S, Suzuki S, Ogata M, Endo T: Aging and oxidative stress in neurodegeneration. Biofactors 1998;7:103-112.
127. Auestad N: Infant nutrition - brain development - disease in later life. An introduction. Dev Neurosci 2000;22:472-473.
128. Yehuda S: Omega-6/omega-3 ratio and brain-related functions. World Rev Nutr Diet 2003;92:37-56.
129. Tilvis RS, Erkinjuntti T, Sulkava R, Miettinen TA: Fatty acids of plasma lipids, red cells and platelets in Alzheinier's disease and vascular dementia. Atherosclerosis 1987;65:237-245.
130. Corrigan FM, Van Rhijn A, Horrobin DF: Essential fatty acids in Alzheimer's disease. Ann NY Acad Sci 1991;640:250-252.
131. Corrigan FM, Mowat B, Skinner ER, Van Rhijn AG, Cousland G: High density lipoprotein fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids 1998;58:125-127.
132. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH: Fatty acid analysis of blood plasma of patients with Alzheinier's disease, other types of dementia, and cognitive impairment. Lipids 2000;35:1305-1312.
133. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ: Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheinier's disease: a case-control study. Br J Nutr 2003;89:483-489.
134. Laurin D, Verreault R, Lindsay J, Dewailly E, Holub BJ: Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimers Dis 2003;5:315-322.
135. Kyle DJ, Schaefer E, Patton G, Beiser A: Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999;34(suppl):S245.
136. May JM, Qu ZC, Morrow JD: Interaction of ascorbate and α-tocopherol in resealed human erythrocyte ghosts. Transmembrane electron transfer and protection from lipid peroxidation. J Biol Chem 1996;271:10577-10582.
137. Simon JA: Vitamin C and cardiovascular disease: a review. J Am Coll Nutr 1992;11:107-125.
138. Jacob RA, Otradovec CL, Russell RM, Munro HN, Hartz SC, McGandy RB, Morrow FD, Sadowski JA: Vitamin C status and nutrient interactions in a healthy elderly population. Am J Clin Nutr 1988;48:1436-1442.
139. Hornig D: Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann NY Acad Sci 1975;258:103-118.
140. Traber MG, Kayden HJ: Tocopherol distribution and intracellular localization in human adipose tissue. Am J Clin Nutr 1987;46:488-495.
141. Duthie G, Wahle K, James W: Oxidants, antioxidants and cardiovascular disease. Nutr Res Rev 1989;2:51-62.
142. Steinberg HO, Baron AD: Vascular function, insulin resistance and fatty acids. Diabetologia 2002;45:623-634.
143. Packer L: Vitamin E is nature's master antioxidant. Sci Am Sci Med 1994;1:54-63.
144. Bendich A, Shapiro SS: Effect of β-carotene and canthaxanthin on the immune responses of the rat. J Nutr 1986;116:2254-2262.
145. Ness AR, Powles JW, Khaw KT: Vitamin C and cardiovascular disease: a systematic review. J Cardiovasc Risk 1996;3:513-521.
146. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-629S.
147. Braughler JM, Hall ED: Involvement of lipid peroxidation in CNS injury. J Neurotrauma 1992;9(suppl 1):S1-S7.
148. Polidori MC, Mecocci P: Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 2002;4:517-522.
149. Tagami M, Ikeda K, Yamagata K, Nara Y, Fujino H, Kubota A, Numano F, Yamori Y: Vitamin E prevents apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Lab Invest 1999;79:609-615.
150. Charlton KE, Rabinowitz TL, Geffen LN, Dhansay MA: Lowered plasma vitamin C, but not vitamin E, concentrations in dementia patients. J Nutr Health Aging 2004;8:99-107.
151. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G: Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989;35:275-282.
152. Riviere S, Birlouez-Aragon I, Nourhashemi F, Vellas B: Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry 1998;13:749-754.
153. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT: Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 1999;92:39-45.
154. McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S, Passmore AP: Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 2001;94:485-490.
155. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003;24:915-919.
156. Polidori MC, Mattioli P, Aldred S, Cecchetti R, Stahl W, Griffiths H, Senin LI, Sies H, Mecocci P: Plasma antioxidant status, immunoglobulin-γ oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 2004;18:265-270.
157. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR: Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 1998;13:840-845.
158. Paraskevas GP, Kapaki E, Libitaki G, Zournas C, Segditsa I, Papageorgiou C: Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol Scand 1997;96:88-90.
159. Cherubini A, Martin A, Andres-Lacueva C, Di Iorio A, Lamponi M, Mecocci P, Bartali B, Corsi A, Senin U, Ferrucci L: Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiol Aging 2005;26:987-994.
160. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC: Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 1992;21:91-94.
161. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, Emeriau JP, Rainfray M: Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001;30:235-241.
162. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF: Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002;59:794-798.
163. Ryglewicz D, Rodo M, Kunicki PK, Bednarska-Makaruk M, Graban A, Lojkowska W, Wehr H: Plasma antioxidant activity and vascular dementia. J Neurol Sci 2002;203-204:195-197.
164. Nes M, Sem SW, Rousseau B, Bjorneboe GE, Engedal K, Trygg K, Pedersen JI: Dietary intakes and nutritional status of old people with dementia living at home in Oslo. Eur J Clin Nutr 1988;42:581-593.
165. Engelhart MJ, Ruitenberg A, Meijer J, Kiliaan A, van Swieten JC, Hofman A, Witteman JC, Breteler MM: Plasma levels of antioxidants are not associated with Alzheimer's disease or cognitive decline. Dement Geriatr Cogn Disord 2005;19:134-139.
166. Helmer C, Peuchant E, Letenneur L, Bourdel-Marchasson I, Larrieu S,
167. Rubba P, Mancini M, Fidanza F, Leccia G, Riemersma RA, Gey KF: Plasma vitamin E, apolipoprotein B and HDL-cholesterol in middle-aged men from southern Italy. Atherosclerosis 1989;77:25-29.
168. Kushner I, Feldmann G: Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med 1978;148:466-477.
169. Kaplan MH, Volanakis JE: Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112:2135-2147.
170. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-1357.
171. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB: Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000;46:934-938.
172. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE: Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-716.
173. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB: Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999;20:954-959.
174. De Maat MP, Kluft C: Determinants of C-reactive protein concentration in blood. Ital Heart J 2001;2:189-195.
175. Heilbronn LK, Noakes M, Clifton PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001;21:968-970.
176. Albert MA, Glynn RJ, Ridker PM: Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003;107:443-447.
177. Ford ES: Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology 2002;13:561-568.
178. Reynolds GD, Vance RP: C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987;111:265-269.
179. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-1392.
180. Kushner I, Rakita L, Kaplan MH: Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest 1963;42:286-292.
181. Yasojima K, Schwab C, McGeer EG, McGeer PL: Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 2000;887:80-89.
182. Iwamoto N, Nishiyama E, Ohwada J, Arai H: Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 1994;177:23-26.
183. Duong T, Nikolaeva M, Acton PJ: C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res 1997;749:152-156.
184. 2-macroglobulin and C-reactive protein. Brain Res 1993;629:245-252.
185. 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. J Neuroimmunol 1995;57:71-75.
186. Strandberg TE, Tilvis RS: C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000;20:1057-1060.
187. Malaguarnera M, Bella R, Alagona G, Ferri R, Carnemolla A, Pennisi G: Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med 2004;15:381-386.
188. Giometto B, Argentiero V, Sanson F, Ongaro G, Tavolato B: Acute-phase proteins in Alzheimer's disease. Eur Neurol 1988;28:30-33.
189. Lawlor BA, Swanwick GR, Feighery C, Walsh JB, Coakley D: Acute phase reactants in Alzheimer's disease. Biol Psychiatry 1996;39:1051-1052.
190. 1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000;103:97-102.
191. Licastro F, Pedrini S, Davis LJ, Caputo L, Tagliabue J, Savorani G, Cucinotta D, Annoni G: Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. Alzheimer Dis Assoc Disord 2001;15:51-55.
192. Chan Carusone S, Smieja M, Molloy W, Goldsmith CH, Mahony J, Chernesky M, Gnarpe J, Standish T, Smith S, Loeb M: Lack of association between vascular dementia and Chlamydia pneumoniae infection: a case-control study. BMC Neurol 2004;4:15.
193. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-174.
194. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM: Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol 2004;61:668-672.
195. Eikelenboom P, Rozemuller JM, van Muiswinkel FL: Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol 1998;154:89-98.